ABCELLERA BIOLOGICS (8QQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ABCELLERA BIOLOGICS (8QQ) has a cash flow conversion efficiency ratio of -0.036x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-34.74 Million ≈ $-40.62 Million USD) by net assets (€966.90 Million ≈ $1.13 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABCELLERA BIOLOGICS (8QQ) balance sheet quality index to measure how much of total assets are equity-financed.
ABCELLERA BIOLOGICS - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how ABCELLERA BIOLOGICS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ABCELLERA BIOLOGICS earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
ABCELLERA BIOLOGICS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ABCELLERA BIOLOGICS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Lier High Temperature Materials Co Ltd
SHE:002392
|
0.010x |
|
Alphatec Holdings Inc
NASDAQ:ATEC
|
0.071x |
|
Cairn Homes PLC
IR:C5H
|
-0.020x |
|
Bitfarms Ltd.
NASDAQ:KEEL
|
-0.131x |
|
Cosmo Pharmaceuticals N.V
F:C43
|
0.013x |
|
Xiamen King Long Motor Group Co Ltd
SHG:600686
|
-0.128x |
|
Gudeng Precision Industrial Co Ltd
TWO:3680
|
0.012x |
|
Rizhao Port Co Ltd
SHG:600017
|
0.056x |
Annual Cash Flow Conversion Efficiency for ABCELLERA BIOLOGICS (2021–2025)
The table below shows the annual cash flow conversion efficiency of ABCELLERA BIOLOGICS from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see 8QQ stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €966.90 Million ≈ $1.13 Billion |
€-131.29 Million ≈ $-153.50 Million |
-0.136x | -32.10% |
| 2024-12-31 | €1.06 Billion ≈ $1.23 Billion |
€-108.56 Million ≈ $-126.91 Million |
-0.103x | -169.95% |
| 2023-12-31 | €1.15 Billion ≈ $1.35 Billion |
€-43.88 Million ≈ $-51.30 Million |
-0.038x | -116.93% |
| 2022-12-31 | €1.23 Billion ≈ $1.44 Billion |
€277.36 Million ≈ $324.26 Million |
0.225x | -5.68% |
| 2021-12-31 | €1.03 Billion ≈ $1.20 Billion |
€244.58 Million ≈ $285.94 Million |
0.238x | -- |
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more